KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- The Complex Issues, Opportunities for Pharmacists in Addressing Medication Adherence September 18, 2025While experts agree there is no one-size-fits-all approach, addressing medication nonadherence among patients presents opportunities for pharmacists to set themselves apart as medication counselors.
- Pharmacists Can Help Manage Therapies for Hyperkalemia September 18, 2025Hyperkalemia, chronic kidney disease, and hypertension often don’t manifest until the diseases become chronically uncontrolled, according to Ralph J. Riello III, PharmD, BCPS.
- Weekly GLP-1s Significantly Reduce Cardiovascular Risks September 18, 2025In an exploration of cardiovascular outcomes, health care utilization, and patient costs, researchers compare glucagon-like peptide-1s with alternative noninsulin glucose-lowering therapies.
- Evidence-Based Hyperkalemia Management: Translating Guidelines Into Pharmacy Practice September 18, 2025
- More Than a Number: Reframing Hyperkalemia Management Across the Care Continuum September 18, 2025An interview with Ralph J. Riello III, PharmD, BCPs.
- Dispensing Leadership: The Dominoes Are Falling in Community Pharmacy September 17, 2025This episode explores how recent trends in the retail community pharmacy industry are informing the actions of pharmacy leadership and their teams across the country.
- FDA Approves Denosumab-Kyqq as Biosimilar for Prolia, Xgeva September 17, 2025The FDA also grants the biosimilar provisional interchangeability designation, making the drug substitutable at the pharmacy level.
- Q&A: Using Data, Addressing Patient Barriers Can Effectively Improve Medication Adherence September 17, 2025In part 3 of our interview with Andrew Maiorini, PharmD, FAHM, vice president of clinical programs at PerformRx, he discusses the ways in which his company is helping patients stay adherent on their medications.
- Proactive, Data-Driven Approach Necessary to Improve Pharmacy Purchasing September 17, 2025Calvin Hunsicker, founder & chief product officer at SureCost, discusses ongoing pharmacy procurement challenges in 2025 and how his company is helping businesses tackle common obstacles.
- Q&A: Pharmacists Play Essential Role in Women' Health Care September 17, 2025Pharmacists enhance menstrual pain management by integrating holistic strategies, empowering women with personalized care and evidence-based guidance for better health outcomes.
Pharmacy Times articles
- Effectively Managing Immunizations in the Long-Term Care Setting September 18, 2025Long-term care pharmacists are significant in lessening the vaccine hesitancy hurdle among facility residents.
- Creating a Culture of Quality in Fast-Melt Tablet Development September 18, 2025Discover the benefits of fast melt tablets, designed for easy swallowing and quick disintegration, enhancing patient convenience and adherence.
- Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety September 18, 2025Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.
- NCPA Announces Keynote Speaker for Annual Convention September 18, 2025
- Triazole Antifungal Therapy: The Clinical Utilization of Therapeutic Drug Monitoring September 18, 2025Pharmacists play a critical role in optimizing triazole therapy in preventing and managing invasive fungal infections.
- High Glucose Levels Associated With Worse Outcomes After Acute Myocardial Infarction September 18, 2025Fluctuations in glycemic delta, a specific measurement of glucose levels, is an indicator of worsened myocardial infarction outcomes, including greater reductions in left ventricular ejection fraction.
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues September 18, 2025The extensive selection of OTC products for GI problems can be challenging for patients to navigate.
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma September 18, 2025An expert discusses the benefits of anti-CD38 quadruplet regimens for elderly multiple myeloma patients.
- IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma September 18, 2025An expert discusses CAR T therapy's potential in treating relapsed multiple myeloma, highlighting long-term remissions and access challenges.
- West Coast Health Alliance Sets Clinical Priorities Amid Vaccine Guidance Shifts September 17, 2025West Coast states unite to enhance vaccine access and guidance for respiratory viruses, prioritizing public health and safety ahead of the 2025-26 season.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com